Phase 3
Stories
-
New Phase 3 trials registered, week of October 12, 2026: 10 industry trials
Industry sponsors registered 10 Phase 3 trials on ClinicalTrials.gov so far in the week of October 12 to 18, 2026. They plan to enroll 22,480 participants in all; the largest, GlaxoSmithKline's RZV vaccine trial, plans to enroll 16,390.
-
Phase 3 results posted, week of October 12, 2026: 11 industry trials
Industry sponsors posted results for 11 Phase 3 trials on ClinicalTrials.gov so far in the week of October 12 to 18, 2026. Together the trials enrolled 4,030 participants; the largest, Sanofi's AERIFY-1 trial, enrolled 1,127.
-
New Phase 3 trials registered, week of September 28, 2026: 9 industry trials
Industry sponsors registered 9 Phase 3 trials on ClinicalTrials.gov in the week of September 28 to October 4, 2026. They plan to enroll 7,514 participants in all; the largest, GlaxoSmithKline's mRNA Seasonal Flu vaccine trial, plans to enroll 3,000.
-
Phase 3 results posted, week of September 28, 2026: 8 industry trials
Industry sponsors posted results for 8 Phase 3 trials on ClinicalTrials.gov in the week of September 28 to October 4, 2026. Together the trials enrolled 3,200 participants; the largest, Teva Pharmaceuticals USA's Estradiol trial, enrolled 1,050.
-
New Phase 3 trials registered, week of October 5, 2026: 11 industry trials
Industry sponsors registered 11 Phase 3 trials on ClinicalTrials.gov in the week of October 5 to 11, 2026. They plan to enroll 6,829 participants in all; the largest, Shanghai Henlius Biotech's NCT07865910 trial, plans to enroll 1,438.
-
Phase 3 results posted, week of October 5, 2026: 12 industry trials
Industry sponsors posted results for 12 Phase 3 trials on ClinicalTrials.gov in the week of October 5 to 11, 2026. Together the trials enrolled 5,329 participants; the largest, Sanofi's AERIFY-2 trial, enrolled 1,234.